Neurocrine Biosciences develops and sells medications targeting neurological, psychiatric, endocrine, and immunological conditions across global markets. The company markets drugs including INGREZZA for tardive dyskinesia and Huntington's chorea, Orilissa for endometriosis, Oriahnn for uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia, alongside several other approved treatments. Its pipeline includes multiple investigational candidates addressing movement disorders, depression, schizophrenia, Alzheimer's disease, epilepsy, obesity, and other neuropsychiatric conditions, supported by partnerships with major pharmaceutical firms.
1Y: 146.78 (+6.3%) · range 123.10–185.50
entry readiness 34 · NOT READY · exit proximity 0
Value area 149.49–180.73 · 74% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -3.07% | +2.67% | mature |
| 40d | -11.88% | +2.67% | mature |